Description
Cilengitide is a cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide that acts as an integrin αVβ3 receptor antagonist. It inhibits adhesion and induces apoptosis of U87MG and U373MG malignant glioma (MG) cells, but not U251MG cells that lack the integrin αVβ3 receptor, in vitro at a concentration of 20 μg/ml.
Cilengitide is a cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide that acts as an integrin αVβ3 receptor antagonist. It inhibits adhesion and induces apoptosis of U87MG and U373MG malignant glioma (MG) cells, but not U251MG cells that lack the integrin αVβ3 receptor, in vitro at a concentration of 20 μg/ml.
Alternate Name/Synonyms: EMD-121974,cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N-methyl-L-valyl)
Appearance: Crystalline solid
Formulation:
CAS Number: 188968-51-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₇H₄₀N₈O₇
Molecular Weight: 588.7
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: >20 mg/ml (DMSO) in 0
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: An integrin αVβ3 receptor antagonist
MDL Number:
PubChem CID: 176873
SMILES: CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
InChi: InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
InChi Key: AMLYAMJWYAIXIA-VWNVYAMZSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |